Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.

Article  PubMed  CAS  Google Scholar 

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098–103.

Article  PubMed  Google Scholar 

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T Cell–engaging antibody. Science. 2008;321:974–7.

Article  PubMed  CAS  Google Scholar 

BLINCYTO® (blinatumomab) for injection.

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31.

Article  PubMed  PubMed Central  Google Scholar 

Dasatinib–Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med [Internet]. https://doi.org/10.1056/NEJMoa2016272

Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320–33.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392:875–91.

Article  PubMed  CAS  Google Scholar 

Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, et al. Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17:776–85.

Article  PubMed  CAS  Google Scholar 

Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478–83.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2:1522–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. MAbs. 2019;11:639–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Viardot A, Goebeler M-E, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131:1094–105.

Article  PubMed  CAS  Google Scholar 

Alderuccio JP, Alencar AJ, Schatz JH, Kuker RA, Pongas G, Reis IM, et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024;12:e23–34.

Article  PubMed  Google Scholar 

Bumma N, Papadantonakis N, Advani AS. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. Future Oncol. 2015;11:1729–39.

Article  PubMed  CAS  Google Scholar 

Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci. 1995;92:7021–5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593-605.

Article  PubMed  CAS  Google Scholar 

Pharmacokinetics of Monoclonal Antibodies-Ryman-2017-CPT: Pharmacometrics & Systems Pharmacology-Wiley Online Library [Internet]. [cited 2025 Jun 22]. https://doi.org/10.1002/psp4.12224.

Poussin M, Sereno A, Wu X, Huang F, Manro J, Cao S, et al. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. J Immunother Cancer. 2021;9: e002444.

Article  PubMed  PubMed Central  Google Scholar 

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41:2238–47.

Article  PubMed  CAS  Google Scholar 

Karimi Y. 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. ASH; 2024. https://ash.confex.com/ash/2024/webprogram/Paper198714.html. Accessed 24 Nov 2024.

Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38:2653–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vose JM, Cheah CY, Clausen MR, Cunningham D, Farooq U, Feldman T, et al. 3-Year update from the Epcore NHL-1 Trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. Blood. 2024;144:4480.

Article  Google Scholar 

Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2024;42:3581–92.

Article  PubMed  CAS  Google Scholar 

Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med [Internet]. 2022. https://www.nature.com/articles/s41591-022-01969-y. Accessed 28 Sept 2022.

Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307–15.

PubMed  PubMed Central  CAS  Google Scholar 

Karimi Y, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). J Clin Oncol. 2024;42:7039–7039.

Article  Google Scholar 

Brody JD, Joergensen JM, Belada D, Costello R, Trneny M, Vitolo U, et al. Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2. J Clin Oncol. 2024;42:7037–7037.

Article  Google Scholar 

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma | N Engl J Med [Internet]. https://doi.org/10.1056/NEJMoa2206913.

Dickinson M. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH; 2024. https://ash.confex.com/ash/2024/webprogram/Paper194333.html. Accessed 21 Nov 2024.

Genentech: Press Releases | Tuesday, May 20, 2025 [Internet]. https://www.gene.com/media/press-releases/15061/2025-05-20/genentech-provides-update-on-fda-advisor?utm_source=chatgpt.com. Accessed 3 Jul 2025.

May 20-21, 2025: Meeting of the Oncologic Drugs Advisory Committee-05/20/2025 [Internet]. FDA. 2025. https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025. Accessed 17 Jun 2025.

Allan J. Indirect comparisons of the efficacy of epcoritamab vs glofitamab in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). ASH; 2024. https://ash.confex.com/ash/2024/webprogram/Paper203994.html. Accessed 24 Nov 2024.

Bartlett N. Subcutaneous mosunetuzumab leads to high rates of durable responses, low rates of cytokine release syndrome, and non-inferior exposure compared with intravenous administration in patients with Relapsed/Refractory follicular lymphoma: primary analysis of a pivotal phase II. ASH; 2024. https://ash.confex.com/ash/2024/webprogram/Paper194612.html. Accessed 20 Nov 2024.

Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. 2025;145:708–19.

Article  PubMed  CAS